Insider Transactions Reported by 20 Insiders of PLIANT THERAPEUTICS, INC.

Symbol
PLRX on Nasdaq
Location
South San Francisco, CA

Insiders trading volume in the past year

PLIANT THERAPEUTICS, INC. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Third Rock Ventures III, L.P. 10%+ Owner $68,438,025 29 Nov 2022
Hans Hull Chief Business Officer $2,920,870 23 Jan 2025
Eric Lefebvre Chief Medical Officer $2,640,879 23 Jan 2025
Mike Ouimette General Counsel & Corp. Sec'y $1,160,287 23 Jan 2025
Bernard Coulie President and CEO, Director $1,146,535 -$114,400 -9.1% 22 Jan 2026
Keith Lamont Cummings Chief Financial Officer $380,433 -$30,723 -7.5% 22 Jan 2026
Steve E. Krognes Director $111,338 05 Jun 2025
Lily Cheung Chief Human Resource Officer $57,404 -$9,644 -14% 22 Jan 2026
Curnutte John T. Director $55,669 05 Jun 2025
David E. I. Pyott Director $55,669 05 Jun 2025
Darren S. Cline Director $55,669 05 Jun 2025
Katharine Knobil Director $55,669 05 Jun 2025
Smital Shah Director $55,669 13 Jun 2024
Hoyoung Huh Director $55,669 05 Jun 2025
Gayle A. Crowell Director $55,669 05 Jun 2025
Thomas A. Mccourt Director $55,669 05 Jun 2025
Suzanne Louise Bruhn Director $55,669 05 Jun 2025
Minnie Kuo Chief Operating Officer $48,391 -$8,854 -15% 22 Jan 2026
Neil Exter Director 16 Jun 2022
Charles J. Homcy Director 29 Jun 2021

Recent Insider Transactions by Companies or Individuals for PLIANT THERAPEUTICS, INC.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Keith Lamont Cummings PLRX Stock Option (Right to Buy) Award 400,000 400,000 22 Jan 2026 Direct
Minnie Kuo PLRX Stock Option (Right to Buy) Award 300,000 300,000 22 Jan 2026 Direct
Lily Cheung PLRX Stock Option (Right to Buy) Award 300,000 300,000 22 Jan 2026 Direct
Bernard Coulie PLRX Stock Option (Right to Buy) Award 1,230,000 1,230,000 22 Jan 2026 Direct
Keith Lamont Cummings PLRX Common Stock Sale -7.47% $30,723 $1.28 -24,002 297,214 20 Jan 2026 Direct
Lily Cheung PLRX Common Stock Sale -14.4% $9,644 $1.28 -7,534 44,847 20 Jan 2026 Direct
Bernard Coulie PLRX Common Stock Sale -15% $114,400 $1.28 -89,375 505,601 20 Jan 2026 Direct
Minnie Kuo PLRX Common Stock Sale -15.5% $8,854 $1.28 -6,917 37,806 20 Jan 2026 Direct
Suzanne Louise Bruhn PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
Katharine Knobil PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
Thomas A. Mccourt PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
Curnutte John T. PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
Steve E. Krognes PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
Darren S. Cline PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
David E. I. Pyott PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
Hoyoung Huh PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
Gayle A. Crowell PLRX Common Stock (Right to Buy) Award 30,000 30,000 05 Jun 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.